天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> European Neuropsychopharmacology >>article
European Neuropsychopharmacology

European Neuropsychopharmacology

IF: 6.09
Download PDF

Agomelatine: A narrative review

Published:1 September 2011 DOI: 10.1016/j.euroneuro.2011.07.004 PMID: 21835598
Koen Demyttenaere

Abstract

Long-term antidepressant treatment success should be viewed as the result of the cumulative effects of treatment at each stage of major depressive disorder (MDD), and as a balance between efficacy and tolerability/safety. Depression is a heterogeneous disorder and different mechanisms of action of different antidepressants probably capitalize on this response heterogeneity. Results from clinical trials with agomelatine, a melatonergic receptor agonist (MT1/MT2) and 5HT2C receptor antagonist, have shown that it is efficacious in both the acute phase and the continuation phase of treatment of depression. Agomelatine's efficacy is observed in different depressive symptom clusters (core depression symptoms, sleep symptoms, anxiety, retardation, somatic symptoms, and work and activities). Active comparator trials show at least comparable efficacy with other antidepressants (paroxetine, venlafaxine, sertraline, fluoxetine) and efficacy has also been demonstrated in severe depression and in treating anxiety symptoms associated with major depression. The tolerability profile shows some clinically significant advantages especially in the lower incidence of treatment emergent sexual dysfunction and of weight gain, two adverse events experienced by patients as most bothersome. Transient aminotransferase elevations without clinical signs of liver damage have been observed more frequently than with placebo (1.1% versus 0.7%), and a hepatic monitoring schedule is therefore recommended.

Substances (8)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Agomelatine 138112-76-2 C15H17NO2 623 suppliers $5.00-$2500.00
Melanotan II 121062-08-6 C50H69N15O9 406 suppliers $35.00-$3154.84
Venlafaxine 93413-69-5 C17H27NO2 258 suppliers $10.00-$1797.00
Paroxetine 61869-08-7 C19H20FNO3 240 suppliers Inquiry
Fluoxetine 54910-89-3 C17H18F3NO 206 suppliers Inquiry
Sertraline 79617-96-2 C17H17Cl2N 174 suppliers Inquiry
Muscarinic toxin 1 13 suppliers $290.70-$2000.00
5HT2C Receptor peptide 6 suppliers Inquiry

Similar articles

IF:4.3

Pharmacological properties of baicalin on liver diseases: a narrative review.

Neural Regeneration Research Jin-Yu Yang, Min Li,etc Published: 1 October 2021
IF:3.2

Roxadustat for Patients with Post-transplant Anemia: A Narrative Review

Neural Regeneration Research Xiaoxiao Tang, Fei Liu,etc Published: 10 November 2023
IF:4.8

Current uses of chlorhexidine for management of oral disease: a narrative review

Neural Regeneration Research Zo? L.S. Brookes , Raul Bescos ,etc Published: 1 December 2020